Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NAMPT | P43490 | 3/20 | 0.65 |
| ▸ | HPGD | P15428 | 2/20 | 0.64 |
| ▸ | MAPT | P10636 | 2/20 | 0.64 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.64 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.64 |
| ▸ | HTT | P42858 | 1/20 | 0.64 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.57 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.57 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.57 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.55 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.53 |
| ▸ | RAB9A | P51151 | 3/20 | 0.51 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.51 |
| ▸ | NPC1 | O15118 | 2/20 | 0.51 |
| ▸ | KLK7 | P49862 | 2/20 | 0.50 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.50 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.50 |
| ▸ | AKT1 | P31749 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13841453 | 0.85 | NAMPT (0.60) | NAMPTHPGDMAPTHTTALDH1A1 | |
| SCHEMBL25701 | 0.85 | ALDH1A1 (0.63) | HPGDMAPTALOX12MAPK1HTT | |
| SCHEMBL588524 | 0.84 | HPGD (0.86) | HPGDMAPTALOX12MAPK1HTT | |
| SCHEMBL13361134 | 0.84 | NAMPT (0.59) | NAMPTHPGDMAPTALOX12MAPK1 | |
| SCHEMBL9125307 | 0.84 | ALDH1A1 (0.65) | HPGDMAPTALOX12MAPK1HTT | |
| SCHEMBL13841456 | 0.83 | MAPK1 (0.60) | NAMPTHPGDMAPK1HTTALDH1A1 | |
| SCHEMBL3364875 | 0.83 | KDM4E (0.56) | HPGDMAPTALOX12MAPK1HTT | |
| SCHEMBL16712168 | 0.83 | NAMPT (0.54) | NAMPTHPGDAKT1 | |
| SCHEMBL3220642 | 0.82 | ALDH1A1 (0.53) | NAMPTHPGDMAPTALOX12MAPK1 | |
| SCHEMBL17183962 | 0.82 | ALDH1A1 (0.60) | HPGDMAPTALOX12MAPK1HTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-101356173-A | Novel pyridopyrazines and their use as modulators of kinases | AETERNA ZENTARIS GMBH (DE) | 2009-01-28 | — | — | CN | claimed |
| EP-1957487-A1 | NOVEL PYRIDOPYRAZINES AND THEIR USE AS MODULATORS OF KINASES | AEterna Zentaris GmbH (DE) | 2008-08-20 | — | — | EP | claimed |
| US-20070149484-A1 | NOVEL PYRIDOPYRAZINES AND THEIR USE AS MODULATORS OF KINASES | ZENTARIS GMBH (DE) | 2007-06-28 | — | — | US | claimed |
| WO-2007054556-A1 | NOVEL PYRIDOPYRAZINES AND THEIR USE AS MODULATORS OF KINASES | ÆTERNA ZENTARIS GMBH (DE) | 2007-05-18 | — | — | WO | claimed |
| EP-1377589-A1 | OXAZOLYL-PYRAZOLE DERIVATIVES AS KINASE INHIBITORS | Pharmacia Italia S.p.A. (IT) | 2004-01-07 | — | — | EP | claimed |
| WO-2002062804-A1 | OXAZOLYL-PYRAZOLE DERIVATIVES AS KINASE INHIBITORS | PHARMACIA ITALIA S.P.A. (IT) | 2002-08-15 | — | — | WO | claimed |
| US-20130157976-A1 | NOVEL PYRIDOPYRAZINES AND THEIR USE AS MODULATORS OF KINASES | CLAUS ECKHARD (DE) | 2013-06-20 | — | — | US | disclosed |
| CN-101356173-B | Novel pyridopyrazines and their use as modulators of kinases | AETERNA ZENTARIS GMBH | 2012-10-31 | — | — | CN | disclosed |
| US-20120252760-A1 | NOVEL PYRIDOPYRAZINES AND THEIR USE AS MODULATORS OF KINASES | ZENTARIS GMBH (DE) | 2012-10-04 | — | — | US | disclosed |
| US-8217042-B2 | Pyridopyrazines and their use as modulators of kinases | ZENTARIS GMBH (DE) | 2012-07-10 | — | — | US | disclosed |
| CN-101356173-A | Novel pyridopyrazines and their use as modulators of kinases | AETERNA ZENTARIS GMBH (DE) | 2009-01-28 | — | — | CN | disclosed |
| EP-1957487-A1 | NOVEL PYRIDOPYRAZINES AND THEIR USE AS MODULATORS OF KINASES | AEterna Zentaris GmbH (DE) | 2008-08-20 | — | — | EP | disclosed |
| US-20070149484-A1 | NOVEL PYRIDOPYRAZINES AND THEIR USE AS MODULATORS OF KINASES | ZENTARIS GMBH (DE) | 2007-06-28 | — | — | US | disclosed |
| WO-2007054556-A1 | NOVEL PYRIDOPYRAZINES AND THEIR USE AS MODULATORS OF KINASES | ÆTERNA ZENTARIS GMBH (DE) | 2007-05-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070149484-A1 | NOVEL PYRIDOPYRAZINES AND THEIR USE AS MODULATORS OF KINASES | MAP4K2, MAP3K15, MAP3K5 | NAMPT 980/4885HPGD 1304/4885MAPT 2551/4885 |
| US-20120252760-A1 | NOVEL PYRIDOPYRAZINES AND THEIR USE AS MODULATORS OF KINASES | MAP4K2, MAP3K15, MAP3K5 | NAMPT 980/4885HPGD 1304/4885MAPT 2551/4885 |
| US-20130157976-A1 | NOVEL PYRIDOPYRAZINES AND THEIR USE AS MODULATORS OF KINASES | MAP4K2, MAP3K15, MAP3K5 | NAMPT 980/4885HPGD 1304/4885MAPT 2551/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.